The University of Southampton
University of Southampton Institutional Repository

Systemic immune-inflammation index predicts the clinical outcome in patients with metastatic renal cell cancer treated with sunitinib.

Systemic immune-inflammation index predicts the clinical outcome in patients with metastatic renal cell cancer treated with sunitinib.
Systemic immune-inflammation index predicts the clinical outcome in patients with metastatic renal cell cancer treated with sunitinib.
Background: In this retrospective analysis, we explored the prognostic and predictive value of the systemic immune-inflammation index (SII), based on lymphocyte, neutrophil, and platelet counts, at baseline and changes at week 6 during first-line sunitinib in patients with metastatic renal cell cancer (RCC).

Results: Patients were stratified into high SII (? 730) and low SII (< 730) groups. SII was associated with objective response, p < 0.0001. The median PFS was 6.3 months (95% CI 5.5–8.9) in patients with SII ? 730 and 18.7 months (95% CI 14.7–22.8) in those with SII < 730, p < 0.0001. The median OS was 43.6 months (95% CI 35.3–52.1) in patients with SII < 730, and 13.5 months (95% CI 9.8–18.5) in those with SII ? 730, p < 0.0001. In multivariate analysis, performance status, IMDC score and SII were able to predict OS (HR = 3.29, HR = 1.71 and HR = 1.79, respectively).

Materials and Methods: We included 335 consecutive RCC patients treated with first-line sunitinib. The X-tile 3.6.1 software (Yale University, New Haven, CT) was used for bioinformatic analysis of the data to determine the cutoff value of SII. Progression-free survival (PFS), overall survival (OS) and their 95% confidence interval (95% CI) were estimated by Kaplan-Meier method and compared with logrank test. The impact of SII conversion at week 6 of treatment on PFS and OS was evaluated by Cox regression analyses.

Conclusions: The SII and its changes during treatment represent a powerful prognostic indicator of clinical outcome in patients with metastatic RCC.
1949-2553
54564-54571
Lolli, Cristian
d0e3a4e8-1016-4311-8d41-9ef4ce9d9ce8
Basso, Umberto
1bab6552-482c-4573-b186-82f50a49d0a4
Derosa, Lisa
812eb77e-a087-4283-b2cd-27f9f1afa50b
Scarpi, Emanuela
9eea50bc-0ad6-4dd6-81ca-a1ec6595b3e4
Sava, Teodoro
c9d5c354-8439-4f26-b966-b560aecf0423
Santoni, Matteo
317ff6c0-4762-4111-926d-463f2b0a5faf
Crabb, Simon J.
bcd1b566-7677-4f81-8429-3ab0e85f8373
Massari, Francesco
0a1a93c0-27fc-49ae-b21b-a4208f5893c0
Aieta, Michele
b4573e11-9bcc-4316-a1ae-5b47e00de5d6
Conteduca, Vincenza
080e2568-d951-455f-8268-2ad478c555f1
Maruzzo, Marco
831e9042-ec7d-406c-99df-cb8a7299cfee
La Russa, Francesca
60127850-eae2-4fbc-ae50-9096c6959f89
Wheater, Matthew
3691c3d8-8589-4693-a0dc-c6a8648cd7df
Berardi, Rossana
4e85c01a-ea41-47d8-ac4b-46a2f42b3a42
Galli, Luca
3e3a1d35-137a-46b9-9028-f7c2c07adb46
De Giorgi, Ugo
86c9f3a7-1680-4a3f-a34f-32cab5d47b4f
Lolli, Cristian
d0e3a4e8-1016-4311-8d41-9ef4ce9d9ce8
Basso, Umberto
1bab6552-482c-4573-b186-82f50a49d0a4
Derosa, Lisa
812eb77e-a087-4283-b2cd-27f9f1afa50b
Scarpi, Emanuela
9eea50bc-0ad6-4dd6-81ca-a1ec6595b3e4
Sava, Teodoro
c9d5c354-8439-4f26-b966-b560aecf0423
Santoni, Matteo
317ff6c0-4762-4111-926d-463f2b0a5faf
Crabb, Simon J.
bcd1b566-7677-4f81-8429-3ab0e85f8373
Massari, Francesco
0a1a93c0-27fc-49ae-b21b-a4208f5893c0
Aieta, Michele
b4573e11-9bcc-4316-a1ae-5b47e00de5d6
Conteduca, Vincenza
080e2568-d951-455f-8268-2ad478c555f1
Maruzzo, Marco
831e9042-ec7d-406c-99df-cb8a7299cfee
La Russa, Francesca
60127850-eae2-4fbc-ae50-9096c6959f89
Wheater, Matthew
3691c3d8-8589-4693-a0dc-c6a8648cd7df
Berardi, Rossana
4e85c01a-ea41-47d8-ac4b-46a2f42b3a42
Galli, Luca
3e3a1d35-137a-46b9-9028-f7c2c07adb46
De Giorgi, Ugo
86c9f3a7-1680-4a3f-a34f-32cab5d47b4f

Lolli, Cristian, Basso, Umberto, Derosa, Lisa, Scarpi, Emanuela, Sava, Teodoro, Santoni, Matteo, Crabb, Simon J., Massari, Francesco, Aieta, Michele, Conteduca, Vincenza, Maruzzo, Marco, La Russa, Francesca, Wheater, Matthew, Berardi, Rossana, Galli, Luca and De Giorgi, Ugo (2016) Systemic immune-inflammation index predicts the clinical outcome in patients with metastatic renal cell cancer treated with sunitinib. Oncotarget, 7 (34), 54564-54571. (doi:10.18632/oncotarget.10515). (PMID:27409344)

Record type: Article

Abstract

Background: In this retrospective analysis, we explored the prognostic and predictive value of the systemic immune-inflammation index (SII), based on lymphocyte, neutrophil, and platelet counts, at baseline and changes at week 6 during first-line sunitinib in patients with metastatic renal cell cancer (RCC).

Results: Patients were stratified into high SII (? 730) and low SII (< 730) groups. SII was associated with objective response, p < 0.0001. The median PFS was 6.3 months (95% CI 5.5–8.9) in patients with SII ? 730 and 18.7 months (95% CI 14.7–22.8) in those with SII < 730, p < 0.0001. The median OS was 43.6 months (95% CI 35.3–52.1) in patients with SII < 730, and 13.5 months (95% CI 9.8–18.5) in those with SII ? 730, p < 0.0001. In multivariate analysis, performance status, IMDC score and SII were able to predict OS (HR = 3.29, HR = 1.71 and HR = 1.79, respectively).

Materials and Methods: We included 335 consecutive RCC patients treated with first-line sunitinib. The X-tile 3.6.1 software (Yale University, New Haven, CT) was used for bioinformatic analysis of the data to determine the cutoff value of SII. Progression-free survival (PFS), overall survival (OS) and their 95% confidence interval (95% CI) were estimated by Kaplan-Meier method and compared with logrank test. The impact of SII conversion at week 6 of treatment on PFS and OS was evaluated by Cox regression analyses.

Conclusions: The SII and its changes during treatment represent a powerful prognostic indicator of clinical outcome in patients with metastatic RCC.

Text
__soton.ac.uk_ude_personalfiles_users_sjc7_mydesktop_10515-160102-2-PB.pdf - Version of Record
Available under License Other.
Download (6MB)

More information

Accepted/In Press date: 23 May 2016
e-pub ahead of print date: 9 July 2016
Organisations: Cancer Sciences

Identifiers

Local EPrints ID: 398109
URI: http://eprints.soton.ac.uk/id/eprint/398109
ISSN: 1949-2553
PURE UUID: 62e30853-7ea4-46ef-bb93-376098e8ae07
ORCID for Simon J. Crabb: ORCID iD orcid.org/0000-0003-3521-9064

Catalogue record

Date deposited: 19 Jul 2016 09:28
Last modified: 15 Mar 2024 03:16

Export record

Altmetrics

Contributors

Author: Cristian Lolli
Author: Umberto Basso
Author: Lisa Derosa
Author: Emanuela Scarpi
Author: Teodoro Sava
Author: Matteo Santoni
Author: Simon J. Crabb ORCID iD
Author: Francesco Massari
Author: Michele Aieta
Author: Vincenza Conteduca
Author: Marco Maruzzo
Author: Francesca La Russa
Author: Matthew Wheater
Author: Rossana Berardi
Author: Luca Galli
Author: Ugo De Giorgi

Download statistics

Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.

View more statistics

Atom RSS 1.0 RSS 2.0

Contact ePrints Soton: eprints@soton.ac.uk

ePrints Soton supports OAI 2.0 with a base URL of http://eprints.soton.ac.uk/cgi/oai2

This repository has been built using EPrints software, developed at the University of Southampton, but available to everyone to use.

We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we will assume that you are happy to receive cookies on the University of Southampton website.

×